Share on LinkedInShare on LinkedIn

ARTICLE · 23 DECEMBER 2019

Artificial Intelligence And The Biopharmaceutical Industry: What's Next?

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

The Situation: Artificial intelligence ("AI") is emerging as a key driver of innovation in the biopharmaceutical industry, which uses AI in research and development ("R&D") to analyze big data.

United StatesIntellectual Property

In Short

The Situation:  Artificial intelligence ("AI") is emerging as a key driver of innovation in the biopharmaceutical industry, which uses AI in research and development ("R&D") to analyze big data.

The Result:  AI is already transforming the R&D process in the biopharmaceutical industry, and that disruption will only increase as AI capabilities expand. At the same time, AI's disruption of traditional concepts of intellectual property ("IP") law will have a significant impact on the biopharmaceutical industry.

Looking Ahead:  The United States Patent and Trademark Office ("USPTO") recently sought public comment on a variety of fundamental questions related to AI, including asking whether new forms of IP protection are needed to protect AI-related innovations. The biopharmaceutical industry in the United States should continue to monitor legal developments as they unfold in the USPTO, Congress, and the courts.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from